[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100565611":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":35,"locations":44,"responsibleParty":64,"collaborators":10,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":10,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":10,"studyType":81,"phases":10,"briefSummary":82,"conditions":83,"keywords":88,"overallStatus":47,"whyStopped":10,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Sun Yat-sen University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Ablation+system group",null,"Participants received ablation of plumonary combined systemic therapy",[13,14],"Procedure: Ablation","Drug: system therapy",{"label":16,"type":10,"description":17,"interventionNames":18},"System group","Participants received systemic therapy",[14],[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"PROCEDURE","Ablation","Ablation including (microwave ablation, radiofrequency ablation, cryoblation), this surgery was conducted under CT guidence. The pulmonary was completely ablated.",[9],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":10},"DRUG","system therapy","Paticipants received systemic therapy according the instructions.",[9,16],[31],{"name":32,"affiliation":33,"role":34},"Feng Duan, MD","Chinese PLA General Hospital","STUDY_DIRECTOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":10,"email":40},"Qunfang Zhou, MD","CONTACT","86 19868000115","zhouqun988509@163.com",{"name":32,"role":38,"phone":42,"phoneExt":10,"email":43},"86 13910984586","duanfeng@vip.sina.com",[45],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Chinese PLA General hospital","RECRUITING","Beijing","Beijing Municipality","100853","China","CN",{"type":54,"coordinates":55},"Point",[56,57],116.39723,39.9075,{"lat":57,"lon":56},[60,62],{"name":37,"role":38,"phone":61,"phoneExt":10,"email":40},"8619868000115",{"name":32,"role":38,"phone":63,"phoneExt":10,"email":43},"8613910984586",{"type":65,"investigatorFullName":66,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Zhou Qunfang","Clinical Professor","100565611","ablation-of-pulmonary-oligometastasis-combined-with-system-for-advanced-hepatocellular-carcinoma-100565611",false,"NCT06644430","Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma","Ablation of Pulmonary Oligometastasis Combined With System Compared System Therapy for Advanced Hepatocellular Carcinoma: a Multicenter Retrospective Study","Inclusion Criteria:\n\n1. diagnosis of primary HCC, confirmed histologically or clinically according to the criteria of the American Association for the Study of Liver Diseases;\n2. presence of pulmonary oligometastasis, the metastases found within three month of HCC diagnosis;\n3. metastases with limited five sites and no more two organs involved, with a maximum diameter of ≤5cm;\n4. receipt of first-line systemic therapy for minimum of 3 months before ablation, with controlled intrahepatic tumors and no progression of metastases. Controlled intrahepatic tumors were defined as those showing a partial or stable response according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST);\n5. undergone locoregional treatments, including transarterial artery chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC) were included;\n6. classified as Child-Pugh class A or B and having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;\n7. no history of other malignancies.\n8. life expectancy more than 3 months;\n9. agreed to participated in this clinical trial;\n10. Hemameba ≥3.0 x109\u002FL, neutrophil ≥1.5x109\u002FL, hemoglobin≥10.0 g\u002FL, platelet≥100x 109\u002FL, ALT; AST; bilirubin ≤1.5-fold normal, GFR≥60ml\u002Fmin.\n\nExclusion Criteria:\n\n1. intermediate HCC;\n2. age \\\u003C 18 years or \\> 75 years;\n3. advanced HCC with more than five metastases;\n4. no response to Lenvatinib;\n5. metastases size \\> 5 cm;\n6. life expectancy less than 3 months.","ALL","18 Years","80 Years",{"count":79,"type":80},470,"ESTIMATED","OBSERVATIONAL","Ablation has been an effective therapy in treating intrathoracic metastases. However, for hepatocellular carcinoma with pulmonary oligometastasis, ablation of metastases remains relatively unexplored and still needs clinical evidence.",[84,85,86,22,87],"Advanced Hepatocellular Carcinoma","Lung Cancer","Oligometastasis","Systemic Therapy",[89,90,91,92,93,94,95,96],"Advanced hepatocellular carcinoma","Lenvatinib","Sorafeinib","Camrelizumab","Tislelizumab","Sintilimab","Toripalimab","Apatinib","2024-12-01",{"date":99,"type":100},"2024-12-03","ACTUAL",{"date":102,"type":100},"2024-10-04",{"date":104,"type":80},"2025-12-30",{"name":5,"class":6},1]